GET DAILY SIGNALSWhy Is Treace Medical Concepts (TMCI) Stock Up +18.86% Today?
Key Takeaways
- TMCI shares surged roughly 18.9% intraday, climbing from a prior close of $4.03 to about $4.79.
- The primary catalyst was a Stifel analyst upgrade to Buy from Hold, with the price target raised to $6.50 from $4.50.
- A secondary driver was last week's third-quarter results, which beat expectations and delivered a positive adjusted EBITDA quarter outside the seasonally strong fourth quarter for the first time since its 2021 IPO.
- The move was amplified by elevated trading volume well above the stock's average daily turnover, typical of a thinly traded small-cap.
- Traders are watching for follow-through buying, the company's narrowed full-year revenue guidance, and broader medtech sector momentum.
- For more context on this stock, explore its Price Targets, Earnings, and Forecast pages.
- Discover AI-driven trading strategies across thousands of tickers on the Trending AI Robots page.
Opening Summary
Treace Medical Concepts, Inc. (TMCI), a Ponte Vedra Beach, Florida-based medical technology company focused on surgical solutions for bunions and related midfoot deformities — best known for its Lapiplasty 3D Bunion Correction system — saw its stock rally sharply on Monday. Shares rose approximately 18.86%, trading near $4.79 versus a prior session close of $4.03. Markets attributed the move primarily to a bullish analyst call, supported by a stronger-than-expected quarterly report released the prior week.
Analyst Upgrade Sparks the Rally
The single biggest catalyst behind the price surge was an upgrade from Stifel, which lifted its rating on TMCI to Buy from Hold and raised its price target to $6.50 from $4.50. The firm's analysts argued the company is positioned for "more visibly positive" revenue growth and improving adjusted EBITDA profitability, citing a multi-year "reboot" that is now producing tangible results. Stifel also highlighted Treace's expansion beyond its core Lapiplasty bunion franchise into adjacent foot and ankle markets, supported by a growing product pipeline still in its early stages of commercialization.
Earnings Momentum and an EBITDA Milestone
The upgrade landed on the heels of Treace's third-quarter results, which exceeded Wall Street's consensus. The company posted a narrower-than-expected loss of $0.19 per share versus the $0.25 loss analysts projected, on revenue of $48.3 million, slightly above the $47.71 million estimate and marking its twelfth consecutive quarterly revenue beat. Most notably, management reported positive adjusted EBITDA of roughly $0.3 million for the quarter — the first time the company has achieved positive adjusted EBITDA outside the seasonally strong fourth quarter since going public in 2021. Investors read this as evidence that the company's profitability inflection is progressing faster than anticipated, even as full-year revenue guidance was narrowed to a range of $206 million to $210 million.
Market Context and Trading Activity
The stock's advance was accompanied by meaningfully elevated trading volume, running well above the company's typical daily average — a common pattern for a lower-float, small-cap name reacting to a single high-impact catalyst. As a specialized orthopedic device maker, TMCI does not move in lockstep with broad indices, and Monday's rally reflected company-specific news rather than a broader market swing. Technically, the surge pushed shares sharply higher off recent trading levels and back toward the upper portion of the stock's 52-week range, underscoring the momentum-driven nature of the move.
What Comes Next for TMCI
Looking ahead, investors will monitor whether TMCI can sustain the post-upgrade momentum and whether other sell-side analysts follow Stifel's more constructive stance. Key watch items include the company's progress toward full-year adjusted EBITDA profitability, the commercial rollout of its newer foot and ankle products, and any updates on procedure volume trends. Risks remain, including a modest year-over-year sales decline in the latest quarter, cautious full-year guidance, and the inherent volatility of a small-cap medical technology stock. Sector developments and broader investor appetite for growth-oriented healthcare names will also influence sentiment in the sessions ahead.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that are currently among the strongest performers in live market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and traded symbols. Only the top-performing bots under present market dynamics are featured in this section. Explore the page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TMCI in upward trend: 10-day moving average moved above 50-day moving average on November 02, 2026
The 10-day moving average for TMCI crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +5.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMCI advanced for three days, in 203 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 129 of 162 cases where TMCI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for TMCI moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 24 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TMCI as a result. In 78 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for TMCI turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 39 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
TMCI moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMCI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TMCI broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.869) is normal, around the industry mean (4.142). P/E Ratio (-4.380) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.430) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. TMCI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMCI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement